Literature DB >> 24065513

PET/CT in malignant lymphoma: basic information, clinical application, and proposal.

Ukihide Tateishi1.   

Abstract

Coregistered fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) provides functional and morphologic data useful for the management of lymphoma. PET/CT is a promising tool in initial staging/re-staging, monitoring post-treatment recurrence/exacerbation, and evaluating prognosis at mid-treatment use [interim PET/CT (iPET/CT)]. Many multicenter studies are currently underway to investigate the effectiveness and safety of stratified treatment protocols using iPET/CT. Thus, the establishment of a system focusing on standardization of image quality through established protocols for scanning or quality control (QC) of the acquired data and organization of a core laboratory facility to promote standardization would be beneficial. Uniformity of image quality across multiple institutions can be guaranteed through optimization of imaging conditions and appropriate QC of PET/CT scanners to ensure standardization. Further research is required to ensure the standardization of PET/CT protocols used in the management of malignant lymphoma.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24065513     DOI： 10.1007/s12185-013-1444-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  54 in total

1.  (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.

Authors:  Gerard Moulin-Romsee; Elif Hindié; Xavier Cuenca; Pauline Brice; Didier Decaudin; Myriam Bénamor; Josette Brière; Marcela Anitei; Jean-Emmanuel Filmont; David Sibon; Eric de Kerviler; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

2.  Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?

Authors:  Bhagwant Rai Mittal; Kuruva Manohar; Pankaj Malhotra; Reena Das; Raghava Kashyap; Anish Bhattacharya; Neelam Varma; Subhash Varma
Journal:  Leuk Lymphoma       Date:  2011-07-12

3.  Standardization of image quality across multiple centers by optimization of acquisition and reconstruction parameters with interim FDG-PET/CT for evaluating diffuse large B cell lymphoma.

Authors:  Hiromitsu Daisaki; Ukihide Tateishi; Takashi Terauchi; Mitsuaki Tatsumi; Kazufumi Suzuki; Naoki Shimada; Hiroyuki Nishida; Akihiko Numata; Koji Kato; Koichi Akashi; Mine Harada
Journal:  Ann Nucl Med       Date:  2012-12-22       Impact factor: 2.668

4.  Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus.

Authors:  Michel Meignan; Andrea Gallamini; Emmanuel Itti; Sally Barrington; Corinne Haioun; Aaron Polliack
Journal:  Leuk Lymphoma       Date:  2012-04-23

5.  Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.

Authors:  V Roland; C Bodet-Milin; A Moreau; T Gastinne; B Mahé; V Dubruille; H Maisonneuve; N Juge-Morineau; P Moreau; H Jardel; L Planche; M Mohty; P Moreau; J-L Harousseau; F Kraeber-Bodéré; S Le Gouill
Journal:  Bone Marrow Transplant       Date:  2010-05-31       Impact factor: 5.483

6.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

7.  Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

Authors:  Caroline Bodet-Milin; Cyrille Touzeau; Christophe Leux; Mehmet Sahin; Anne Moreau; Hervé Maisonneuve; Nadine Morineau; Henry Jardel; Philippe Moreau; Céline Gallazini-Crépin; Pascal Gries; Rémy Gressin; Jean-Luc Harousseau; Mohamad Mohty; Philippe Moreau; Françoise Kraeber-Bodere; Steven Le Gouill
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-29       Impact factor: 9.236

8.  (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.

Authors:  Michal Weiler-Sagie; Olga Bushelev; Ron Epelbaum; Eldad J Dann; Nissim Haim; Irit Avivi; Ayelet Ben-Barak; Yehudit Ben-Arie; Rachel Bar-Shalom; Ora Israel
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

9.  18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential.

Authors:  Yuko Watanabe; Hiroaki Suefuji; Yasumitsu Hirose; Hayato Kaida; Gen Suzuki; Jun Uozumi; Etsuyo Ogo; Mayumi Miura; Konomi Takasu; Kanoko Miyazaki; Keita Nakahara; Masatoshi Ishibashi; Takashi Okamura; Koichi Ohshima; Naofumi Hayabuchi
Journal:  Int J Hematol       Date:  2012-12-02       Impact factor: 2.490

10.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

Authors:  K Spaepen; S Stroobants; P Dupont; P Vandenberghe; J Thomas; T de Groot; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976
View more
  5 in total

1.  Assessment of the nature of residual masses at end of treatment in lymphoma patients using volume perfusion computed tomography.

Authors:  R Syha; L Grünwald; T Horger; D Spira; D Ketelsen; W Vogel; C D Claussen; M Horger
Journal:  Eur Radiol       Date:  2013-12-05       Impact factor: 5.315

2.  Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation.

Authors:  Hideki Tsujimura; Toshiko Miyaki; Shuhei Yamada; Takeaki Sugawara; Mikiko Ise; Shintaro Iwata; Tsukasa Yonemoto; Dai Ikebe; Makiko Itami; Kyoya Kumagai
Journal:  Int J Hematol       Date:  2014-07-26       Impact factor: 2.490

3.  Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.

Authors:  Kotaro Miyao; Reona Sakemura; Kanae Imai; Toshiyasu Sakai; Natsuko Tsushita; Tomonori Kato; Keiko Niimi; Yoshitaka Ono; Masashi Sawa
Journal:  Int J Hematol       Date:  2014-06-20       Impact factor: 2.490

4.  Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.

Authors:  Sung-Hoon Jung; Jae-Sook Ahn; Yeo-Kyeoung Kim; Sun-Seog Kweon; Jung-Joon Min; Hee-Seung Bom; Hyeoung-Joon Kim; Yee Soo Chae; Joon Ho Moon; Sang Kyun Sohn; Sang Woo Lee; Byung Hyun Byun; Young Rok Do; Je-Jung Lee; Deok-Hwan Yang
Journal:  BMC Cancer       Date:  2015-03-28       Impact factor: 4.430

5.  Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings.

Authors:  Yu Kong; Lili Qu; Yuekai Li; Dai Liu; Xuemin Lv; Jiankui Han
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.